Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 3/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.41 |
| ▸ | CES2 | O00748 | 2/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | DAO | P14920 | 1/20 | 0.39 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1079930 | 0.87 | CES1 (0.54) | CES1MAPK1SRCALDH1A1LMNA | |
| SCHEMBL583285 | 0.81 | CYP1A2 (0.46) | CES1NPC1RAB9AMAPK1ALDH1A1 | |
| SCHEMBL997814 | 0.81 | CYP1A2 (0.46) | CES1NPC1RAB9AMAPK1ALDH1A1 | |
| SCHEMBL30450959 | 0.81 | CYP1A2 (0.46) | CES1NPC1RAB9AMAPK1ALDH1A1 | |
| SCHEMBL9888570 | 0.81 | CYP1A2 (0.46) | CES1NPC1RAB9AMAPK1ALDH1A1 | |
| SCHEMBL182636 | 0.80 | CES1 (0.52) | CES1NPC1RAB9AMAPK1SRC | |
| SCHEMBL650571 | 0.79 | CES1 (0.61) | CES1NPC1RAB9ASRCALDH1A1 | |
| SCHEMBL404851 | 0.78 | MAPK1 (0.46) | NPC1RAB9AMAPK1ALDH1A1LMNA | |
| SCHEMBL2398996 | 0.78 | MAPT (0.50) | CES1NPC1RAB9AMAPK1ALDH1A1 | |
| SCHEMBL50344 | 0.78 | CES1 (0.48) | CES1NPC1RAB9AMAPK1SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230022724-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-26 | — | — | US | disclosed |
| US-20230013602-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-19 | — | — | US | disclosed |
| US-20230012368-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-12 | — | — | US | disclosed |
| US-20220135591-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF MONOACYLGLYCEROL LIPASE (MAGL) | HOFFMANN-LA ROCHE INC. (US) | 2022-05-05 | — | — | US | disclosed |
| US-10233191-B2 | Fused piperidine amides as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-03-19 | — | — | US | disclosed |
| CN-106083563-B | A kind of method for synthesizing the fluoro- 4- trifluoromethylbenzoic acids of 2- | 沧州普瑞东方科技有限公司 | 2018-05-25 | — | — | CN | disclosed |
| WO-2018052903-A1 | RORγ MODULATORS | THE SCRIPPS RESEARCH INTITUTE (US) | 2018-03-22 | — | — | WO | disclosed |
| CN-107417518-A | To trifluoromethylbenzoic acid synthetic method between a kind of neighbour | 淄博飞源化工有限公司 | 2017-12-01 | — | — | CN | disclosed |
| US-20170145011-A1 | Pyrrolopyrazine-Spirocyclic piperidine amides as modulators of ion channels | VERTEX PHARMA (US) | 2017-05-25 | — | — | US | disclosed |
| US-9617597-B2 | Genetic susceptibility variants associated with cardiovascular disease | DECODE GENETICS EHF (IS) | 2017-04-11 | — | — | US | disclosed |
| US-20070280917-A1 | Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment | DECODE GENETICS, INC. (IS) | 2007-12-06 | — | — | US | disclosed |
| US-7288564-B2 | Indole derivatives | GLAXO GROUP LIMITED (GB) | 2007-10-30 | — | — | US | disclosed |
| US-20060264463-A1 | Chemical compounds | MEDTECH CONVERGENCE FUND, L.P. | 2006-11-23 | — | — | US | disclosed |
| US-20060019269-A1 | Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment | DECODE GENETICS, INC. (IE) | 2006-01-26 | — | — | US | disclosed |
| US-20050272051-A1 | Methods of preventing or treating recurrence of myocardial infarction | DECODE GENETICS EHF. (IS) | 2005-12-08 | — | — | US | disclosed |
| US-20050042674-A9 | Common ligand mimics: thiazolidinediones and rhodanines | TRIAD THERAPEUTICS, INC. | 2005-02-24 | — | — | US | disclosed |
| US-20050019825-A9 | Common ligand mimics: pseudothiohydantoins | TRIAD THERAPEUTICS, INC. | 2005-01-27 | — | — | US | disclosed |
| US-5804346-A | Electrophotographic photoreceptor | MITSUBISHI CHEMICAL CORPORATION (JP) | 1998-09-08 | — | — | US | disclosed |
| US-4990657-A | From an aromatic halide without a phase transfer agent | RHONE-POULENC CHIMIE (FR) | 1991-02-05 | — | — | US | disclosed |
| EP-0038223-A1 | Process for the preparation of trifluoromethylbenzoyl halides | OCCIDENTAL CHEMICAL CORPORATION (US) | 1981-10-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170145011-A1 | Pyrrolopyrazine-Spirocyclic piperidine amides as modulators of ion channels | KCNJ2, KCNJ5, KCNJ1 | CES1 3924/4885NPC1 692/4885RAB9A 2212/4885 |
| US-20230022724-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | MRPL21, O60361, MYD88 | CES1 1005/4885NPC1 750/4885RAB9A 1672/4885 |
| US-20050019825-A9 | Common ligand mimics: pseudothiohydantoins | FGFR3, BID, FLT3 | CES1 3397/4885NPC1 3939/4885RAB9A 4762/4885 |
| US-20060264463-A1 | Chemical compounds | CCR3, CCR1, CCR4 | CES1 1114/4885NPC1 796/4885RAB9A 2167/4885 |
| US-20070280917-A1 | Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment | ALOX15B, ALOX15, ALOX5 | CES1 305/4885NPC1 2179/4885RAB9A 1992/4885 |
| US-10233191-B2 | Fused piperidine amides as modulators of ion channels | TRPV1, TRPA1, KCNJ2 | CES1 3113/4885NPC1 1085/4885RAB9A 1177/4885 |
| US-20220135591-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF MONOACYLGLYCEROL LIPASE (MAGL) | MGLL, LIPC, PNLIP | CES1 12/4885NPC1 449/4885RAB9A 238/4885 |
| US-20050042674-A9 | Common ligand mimics: thiazolidinediones and rhodanines | GPR65, NR2E3, FGFR3 | CES1 3322/4885NPC1 2380/4885RAB9A 2717/4885 |
| US-20230013602-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | IL4, RPS4Y1, RPS4X | CES1 2477/4885NPC1 1239/4885RAB9A 2104/4885 |
| US-20060019269-A1 | Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment | PLAAT3, PLAAT2, PLA2G7 | CES1 412/4885NPC1 3488/4885RAB9A 3327/4885 |
| US-20230012368-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | MRPL21, MYD88, IL1R1 | CES1 1072/4885NPC1 642/4885RAB9A 1773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.